# Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study

> **NCT01190241** · NA · TERMINATED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 45 (actual)

## Conditions studied

- Advanced Solid Tumors
- Inoperable
- Metastasis

## Interventions

- **DRUG:** desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib

## Key facts

- **NCT ID:** NCT01190241
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01190241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01190241, "Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01190241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*